|
|
|
|
 DNDi has been awarded USD 2.34 million for a large-scale leishmaniasis R&D project from a new pooled fund set up by Member States of the WHO. The ‘Leishmaniasis Global R&D and Access Initiative’ aims to demonstrate that R&D for can be incentivized and optimized through various mechanisms to fill R&D gaps. »
|
|
|
 After the successful completion of Phase I human clinical trials for SCYX-7158 (AN5568), the first oral drug candidate specifically developed by DNDi from the earliest drug discovery stage to combat sleeping sickness, DNDi and partners will start a pivotal Phase II/III trial in 2016 in the Democratic Republic of the Congo. »
|
|
|
 DNDi applauds the three winners of the ‘2015 Nobel Prize in Physiology or Medicine’, whose research ultimately led to therapies for the highly debilitating parasitic worm diseases, lymphatic filariasis and river blindness, and the world’s largest parasitic killer, malaria. DNDi hopes it will encourage greater public leadership in innovation and access to treatments for neglected patients. »
|
|
|
 DNDi and Eisai Co., Ltd. have signed an agreement to proceed with the clinical development of Eisai’s anti-fungal drug fosravuconazole for the potential new treatment of eumycetoma, a fungal form of mycetoma, one of the world’s most neglected diseases. »
|
|
|
A little-known, but devastating disease
 Most probably transmitted through pricks to the skin by walking barefoot, eumycetoma is a chronic condition that affects people in tropical and subtropical regions, in particular across Africa, with the highest burden found in Sudan. The fungus penetrates the skin and causes massive tumour-like lesions that lead to serious disability, grave socioeconomic consequences, and stigma. Nineteen years ago, while playing on the school field, Alsadik Mohamed Musa Omer pricked his foot on a thorn. Like any other 15 year old boy, he continued playing…
|
|
|
PLOS Neglected Tropical Diseases:
Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study »
PLOS Neglected Tropical Diseases:
Development and validation of a novel Leishmania donovani screening cascade for high-throughput screening using a novel axenic assay with high predictivity of leishmanicidal intracellular activity »
European Journal of Medicinal Chemistry:
Aminothiazoles: Hit to lead development to identify antileishmanial agents »
BioMed Central Medicine:
Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data »
The Journal of Molecular Diagnostics:
Analytical validation of quantitative real-time PCR methods for quantification of Trypanosoma cruzi DNA in blood samples from Chagas disease patients »
BioMed Central Medicine:
Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data »
PLOS Neglected Tropical Diseases:
A review: The current in vivo models for the discovery and utility of new antileishmanial drugs targeting cutaneous leishmaniasis »
Bioorganic Medicinal Chemistry:
Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation »
Drug Design, Development and Therapy:
Translational challenges of animal models in Chagas disease drug development: A review »
PLOS One:
Antiprotozoal activity profiling of approved drugs: A starting point toward drug repositioning »
PLOS One:
Benznidazole/itraconazole combination treatment enhances anti-Trypanosoma cruzi activity in experimental Chagas disease »
PLOS Neglected Diseases:
Target Product Profile (TPP) for Chagas disease point-of-care diagnosis and assessment of response to treatment »
|
|
|
Photo credits:
DNDi/Don Paul, DNDi/Benoît Marquet
|
|
|
|
|
|
|
|
|
